LEXEO Therapeutics is a New York City-based, clinical-stage gene therapy company focused on addressing some of the most devastating genetically defined cardiovascular and central nervous system diseases affecting both larger-rare and prevalent patient populations. LEXEO’s foundational science stems from partnerships and exclusive licenses with leading academic laboratories at Weill Cornell Medical College and the University of California, San Diego, two preeminent institutions on the cutting edge of gene therapy research. LEXEO is advancing a deep and diverse pipeline of AAV-based gene therapy candidates in rare cardiovascular diseases, APOE4-associated Alzheimer’s disease, and CLN2 Batten disease, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization.
For more information, please visit www.lexeotx.com.
Location: United States, New York
Employees: 11-50
Total raised: $180M
Founded date: 2018
Investors 3
| Date | Name | Website |
| - | PBM Capita... | pbmcap.com |
| - | Omega Fund... | omegafunds... |
| 23.01.2021 | Longitude ... | longitudec... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.03.2024 | - | $95M | - |
| 07.01.2021 | - | $85M | - |
Mentions in press and media 11
| Date | Title | Description | Source |
| 17.03.2024 | Lexeo Therapeutics Closes $95M Financing | Lexeo Therapeutics, a genetic medicine company, secures $95 million in private placement, extending ... | parsers.vc... |
| 13.03.2024 | Lexeo Therapeutics Announces Closing of Oversubscribed $95.0... | - | globenewsw... |
| 13.03.2024 | Lexeo Therapeutics Announces Closing of Oversubscribed $95.0... | Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partn... | einpresswi... |
| 03.11.2023 | Lexeo’s IPO Raises $100M for Gene Therapies That Treat the H... | Precision medicine is a term commonly associated with cancer treatment, but Lexeo Therapeutics appli... | medcitynew... |
| 21.11.2022 | The 10 people transforming healthcare, from companies like M... | Insider Insider's 100 People Transforming Business highlights 100 leaders across 10 industries who a... | businessin... |
| 09.09.2021 | LEXEO Therapeutics, LLC announced that it has received $100 ... | LEXEO Therapeutics, LLC announced that it has received $100,000,000 in a round of funding co-led by ... | marketscre... |
| 09.09.2021 | LEXEO Therapeutics Closes $100 Million Series B Financing to... | Financing led by D1 Capital Partners and Eventide Asset Management with participation from additiona... | marketscre... |
| 08.01.2021 | Daily funding roundup - January 8th, 2021 | SilviaTerra raised $4.4M; Hipcamp landed $57M; DiCE Molecules secured $80M; Affinivax picks up $226M... | vator.tv/n... |
| 07.01.2021 | Lexeo Therapeutics emerges with $85M, 18 gene therapy progra... | Gene therapy veteran Ronald Crystal, M.D., has seen it all. “I’ve been in the gene therapy field sin... | fiercebiot... |
| - | Investors have poured $548 million into neuroscience biotech... | Peter Anastasiou, the CEO of Capsida Biotherapeutics. Capsida Biotherapeutics This story is availabl... | businessin... |
Show more